Vaderis Therapeutics AG
🇨ðŸ‡Switzerland
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.vaderis.com
Assess Safety and Efficacy of VAD044 in HHT Patients
Phase 1
Active, not recruiting
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- Drug: VAD044 Part IDrug: VAD044 Part II
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Vaderis Therapeutics AG
- Target Recruit Count
- 75
- Registration Number
- NCT05406362
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇫🇷Hospices Civils de Lyon, Lyon, France
© Copyright 2025. All Rights Reserved by MedPath